Orion Corp - Company Profile
Powered by
All the data and insights you need on Orion Corp in one report.
- Save hours of research time and resources with
our up-to-date Orion Corp Strategy Report
- Understand Orion Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Orion Corp (Orion) develops, manufactures and markets human and veterinary pharmaceuticals, and active pharmaceutical ingredients (APIs). Its products include pharmaceuticals for the treatment of central nervous system disorders, cancer and respiratory diseases. The company's pipeline encompasses investigational candidates for the treatment of amyotrophic lateral sclerosis, Parkinson’s disease, chronic obstructive pulmonary disease, and various cancer types. Orion’s client base consists of healthcare service providers and professionals, such as doctors, pharmacies, veterinarians, hospitals, healthcare centers, clinics and laboratories. The company sells its products in European markets through its sales network and in international markets through several partners and distributors. Orion is headquartered in Espoo, Finland.
Orion Corp premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Medicines and self-care products: | - |
Nubeqa (darolutamide) | Domitor |
dexdor (dexmedetomidine) | Stalevo |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Contracts/Agreements | In January, the company entered into a research collaboration and licensing agreement with Glykos Finland Oy to create next-generation antibody-drug conjugates. |
2024 | Contracts/Agreements | In January, the company entered into a licensing agreement with Newel Health to develop, manufacture and commercialize ODD-403. |
2023 | Contracts/Agreements | In December, the company entered into a non-binding term sheet for a licensing- and supply agreement with Navamedic for Flexilev and the Orafid dispenser across Europe but not Sweden, Norway, Denmark, and Iceland. |
Competitor Comparison
Key Parameters | Orion Corp | F. Hoffmann-La Roche Ltd | Merck & Co Inc | Abbott Laboratories | GSK plc |
---|---|---|---|---|---|
Headquarters | Finland | Switzerland | United States of America | United States of America | United Kingdom |
City | Espoo | Basel | Rahway | Abbott Park | Brentford |
State/Province | - | - | New Jersey | Illinois | England |
No. of Employees | 3,698 | 103,605 | 72,000 | 114,000 | 70,212 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Mikael Silvennoinen | Chairman | Executive Board | 2020 | 68 |
Liisa Hurme | President; Chief Executive Officer | Senior Management | 2022 | 57 |
Rene Lindell | Chief Financial Officer | Senior Management | 2024 | - |
Hilpi Rautelin | Vice Chairman | Executive Board | 2012 | 63 |
Niclas Lindstedt | Senior Vice President - Animal Health business division | Senior Management | 2023 | 58 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer